Retrospective REDEFINE 1 analyses in 2,309 women showed 25.0% average weight loss on CagriSema at 68 weeks, per Novo, versus 3.0% on placebo.
Recap by typeshit. Full story at ad-hoc-news.de.
Popular Mechanics traces how her 1980s work at Mass General showed GLP-1 triggers insulin release. Gallup now puts GLP-1 weight loss use at about 11% of Americans.
Barzilai highlights trial results on retatrutide in adults with sleep apnea and obesity or overweight, a new use being tested for Lilly's drug.
The Washington meeting runs November 14 to 17, with primary REDEFINE 9 results and pediatric semaglutide research for kids 6 to under 12.
Researchers tracked spending on drinks while out and found a sharp drop among people taking GLP-1 medications.
Politico looks at the warning signs around Health Secretary Kennedy's move to let six peptides that lack FDA approval reach the US market.
Megan Hancocks, 32, told ABC she was hospitalized within a week of two doses bought for cash at a beauty appointment, and still can't work six months later.
Loading…